ArticleESMO open2022

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.

P Vallerio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.